Statins Reduce Appropriate Cardioverter-Defibrillator Shocks and Mortality in Patients With Heart Failure and Combined Cardiac Resynchronization and Implantable Cardioverter-Defibrillator Therapy

Desai, Harit; Aronow, Wilbert S.; Tsai, Fausan S.; Ahn, Chul; Lai, Hoang M.; Amin, Harshad; Gandhi, Kaushang; Frishman, William H.; Cohen, Martin; Sorbera, Carmine

doi:10.1177/1074248409340157

Cited by 22 publications

(20 citation statements)

References 8 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…42,43 The results observed may be secondary to the electrophysiologic mechanisms of statins seen in atrial fibrillation, with improved endothelial function and plaque stabilization also protecting against ischemia-induced arrhythmias.…”

Section: Implantable Cardioverter Defibrillatorsmentioning

confidence: 86%

The Pleiotropic Effects of the Hydroxy-Methyl-Glutaryl-CoA Reductase Inhibitors in Cardiovascular Disease

Mihos

Salas

Santana

2010

Cardiology in Review

View full text Add to dashboard Cite

The hydroxy-methyl-glutaryl-CoA reductase inhibitors (statins) are used extensively in the treatment of hyperlipidemia, and in the long-term prevention of coronary artery disease and stroke. They have also demonstrated a benefit in a variety of other cardiovascular disease processes. These secondary actions are known as pleiotropic effects. An updated discussion on the pleiotropy of statins is provided, and emphasizes the importance of randomized, placebo-controlled trials to further elucidate the potential benefits of these non-lipid-lowering actions in the treatment of cardiovascular disease.

show abstract

Section: Implantable Cardioverter Defibrillatorsmentioning

confidence: 86%

The Pleiotropic Effects of the Hydroxy-Methyl-Glutaryl-CoA Reductase Inhibitors in Cardiovascular Disease

Mihos

Salas

Santana

2010

Cardiology in Review

View full text Add to dashboard Cite

show abstract

“…Further, nicotine has been shown to stimulate the sympathetic nerves and markedly elevate serum catecholamine concentration, which is potentially arrhythmogenic (18). Smoking is indeed a significant risk factor for appropriate ICD shocks among patients with heart failure with an ICD (19)(20)(21). However, it is not certain whether smoking by itself is a risk for idiopathic Vf.…”

Section: Retrospective Survey Of the Medical Recordmentioning

confidence: 99%

Graves' Disease Complicated by Ventricular Fibrillation in Three Men Who Were Smokers

Ando

Henmi²,

Haruta³

et al. 2011

Thyroid

View full text Add to dashboard Cite

Background: Thyrotoxicosis is known to be associated with sinus tachycardia and supraventricular tachyarrhythmias, but rarely with ventricular fibrillation (Vf), which has only occurred in some patients with hypokalemic periodic paralysis or ischemic heart disease. Patient Findings: We present three men who were transferred to our hospital with Graves' disease who developed idiopathic Vf. None of them had hypokalemic periodic paralysis or ischemic heart disease but all were smokers. None of other patients with thyrotoxicosis (587 females and 155 males) who were seen at our hospital, in the period during which the three men were seen, had idiopathic Vf. In our three men with thyrotoxicosis and idiopathic Vf, there was no identifiable underlying heart disease. One of the three patients died of hypoxic encephalopathy. The other two men did not have recurrent Vf after their thyroid function normalized. Summary: These cases and a review of similar cases in the literature imply that improving thyrotoxicosis seems to be effective for treating idiopathic Vf in some patients. Conclusions: Our findings suggest that thyroid hormone excess might play a direct role in the development of Vf in susceptible individuals. Our experience with these three patients suggests that smoking men with thyrotoxicosis likely have an increased risk for Vf, even if they do not have other predisposing factors.

show abstract

“…39 Treatment with statins in 121 of 209 patients with heart failure who had combined cardiac resynchronization-ICD therapy was associated with a 54% reduction in appropriate ICD shocks and with a 95% decrease in mortality. 40 Treatment with statins in 58% of 209 patients with heart failure treated with combined cardiac resynchronization-ICD therapy and in 49% of 320 patients with heart failure treated with an ICD reduced appropriate ICD shocks by 65% and reduced time to mortality by 82%. 41 At 1243 days follow-up of 549 patients with heart failure treated with an ICD, treatment with statins decreased appropriate ICD shocks 46%, inappropriate ICD shocks 48%, and time to all-cause mortality 68%.…”

Section: Observational Studiesmentioning

confidence: 99%

Treatment of Hypercholesterolemia in 2015

Aronow

2017

American Journal of Therapeutics

Self Cite

View full text Add to dashboard Cite

Randomized, double-blind, placebo-controlled secondary prevention and primary prevention studies and observational studies have documented that statins reduce cardiovascular events in high-risk patients with hypercholesterolemia. The 2013 American College of Cardiology/American Heart Association guidelines on treatment of hypercholesterolemia support the use of statins in 4 major groups that will be discussed. The Expert Panel of these guidelines could find no data supporting the routine use of nonstatin drugs combined with statins to further reduce cardiovascular events. Since these guidelines were published, a double-blind randomized trial of 18,144 patients with an acute coronary syndrome demonstrated at a 7-year follow-up that the incidence of cardiovascular events was 34.7% in patients randomized to simvastatin plus placebo versus 32.7% in patients randomized to simvastatin plus ezetimibe (hazard ratio = 0.936; P = 0.016). Proprotein convertase subtilisin/kexin type 9 inhibitors further lower serum low-density lipoprotein cholesterol by 50%-70% in patients treated with statins and 4 phase 3 trials including more than 70,000 patients are investigating whether these monoclonal antibodies to proprotein convertase subtilisin/kexin type 9 will lower cardiovascular events.

show abstract

Statins Reduce Appropriate Cardioverter-Defibrillator Shocks and Mortality in Patients With Heart Failure and Combined Cardiac Resynchronization and Implantable Cardioverter-Defibrillator Therapy

Cited by 22 publications

References 8 publications

The Pleiotropic Effects of the Hydroxy-Methyl-Glutaryl-CoA Reductase Inhibitors in Cardiovascular Disease

The Pleiotropic Effects of the Hydroxy-Methyl-Glutaryl-CoA Reductase Inhibitors in Cardiovascular Disease

Graves' Disease Complicated by Ventricular Fibrillation in Three Men Who Were Smokers

Treatment of Hypercholesterolemia in 2015

Contact Info

Product

Resources

About